The following MDSCs inhibitors have been evaluated in clinical trials (52): Reparixin and AZD5069 (CXCR2 antagonists), respectively, in phase II for breast cancer and in phase Ib/II for advanced solid tumors and metastatic squamous cell carcinoma; Plexidartinib (CSF-1R inhibitor) in phase II for recurrent glioblastoma; Maraviroc (CCR5 antagonist) in phase I for metastatic colorectal cancer. The gene discussed is CCR5; the disease is breast carcinoma.